In 1971, the journal Blood published the first successful HLA matched bone marrow transplantation to treat acute leukemia. Since then, the field of hematopoietic stem cell transplantation (HSCT) has evolved considerably and allogeneic-HSCT is now a standard curative care for several patients with high risk refractory hematologic cancers. Unfortunately, acute graft-versus-host disease (aGVHD) remains the most serious complication to occur after leukemia recurrence with only a small fraction of patients surviving more than 2 years after developing grade 3 or 4 aGVHD. Since 1950, animal models have provided important insights into the physiopathology of aGVHD and collective efforts between clinical and basic scientists to understand the biology of aGVHD have led to seminal findings with regards to the role of histocompatibility, conditioning regimens, lymphocytes, antigen presenting cells, cytokines as well as microbiota in the development and severity of aGVHD.
Moreover, the development of new tools for studying and analyzing large-scale data now allows the acquisition of information and therefore elements of understanding that were not previously accessible. All of these major changes make it necessary to take stock of this medical practice and what it continues to contribute in terms of fundamental knowledge to the field of transplant immunology.
This Research Topic seeks to cover new developments in the field of HSCT with a special emphasis on Graft-Versus-Host Disease and also the role of T Cells. We welcome Original Research, Review/Mini Review, Clinical Trial and Commentary articles focusing on, but not limited to, the following areas of aGvHD:
• New procedures in Allogeneic Stem Cell Transplantation
• Conditioning regimens
• Strategies to reduce/control aGVHD
• T cell depletion, Tregs, mesenchymal stem cells, suicide genes, induction of tolerance, modulation of graft-versus leukemia (cytokines, CAR-T cells)
• Strategies to improve immune reconstitution
• In vitro and in vivo studies of alloreactive T cells
• Animal models
In 1971, the journal Blood published the first successful HLA matched bone marrow transplantation to treat acute leukemia. Since then, the field of hematopoietic stem cell transplantation (HSCT) has evolved considerably and allogeneic-HSCT is now a standard curative care for several patients with high risk refractory hematologic cancers. Unfortunately, acute graft-versus-host disease (aGVHD) remains the most serious complication to occur after leukemia recurrence with only a small fraction of patients surviving more than 2 years after developing grade 3 or 4 aGVHD. Since 1950, animal models have provided important insights into the physiopathology of aGVHD and collective efforts between clinical and basic scientists to understand the biology of aGVHD have led to seminal findings with regards to the role of histocompatibility, conditioning regimens, lymphocytes, antigen presenting cells, cytokines as well as microbiota in the development and severity of aGVHD.
Moreover, the development of new tools for studying and analyzing large-scale data now allows the acquisition of information and therefore elements of understanding that were not previously accessible. All of these major changes make it necessary to take stock of this medical practice and what it continues to contribute in terms of fundamental knowledge to the field of transplant immunology.
This Research Topic seeks to cover new developments in the field of HSCT with a special emphasis on Graft-Versus-Host Disease and also the role of T Cells. We welcome Original Research, Review/Mini Review, Clinical Trial and Commentary articles focusing on, but not limited to, the following areas of aGvHD:
• New procedures in Allogeneic Stem Cell Transplantation
• Conditioning regimens
• Strategies to reduce/control aGVHD
• T cell depletion, Tregs, mesenchymal stem cells, suicide genes, induction of tolerance, modulation of graft-versus leukemia (cytokines, CAR-T cells)
• Strategies to improve immune reconstitution
• In vitro and in vivo studies of alloreactive T cells
• Animal models
